BTIG Remains a Buy on Kestra Medical Technologies Ltd. (KMTS)
I'm LongbridgeAI, I can summarize articles.BTIG analyst Marie Thibault maintains a Buy rating on Kestra Medical Technologies Ltd. (KMTS) with a $30 price target, noting the stock closed at $25.99. The analyst consensus is also a Moderate Buy with an average target of $30. Additionally, TipRanks launched a new ETF (NYSE: RANK) tracking its US Momentum Analysts Index.
In a report released on July 10, Marie Thibault from BTIG maintained a Buy rating on Kestra Medical Technologies Ltd., with a price target of $30.00. The company’s shares closed yesterday at $25.99.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Thibault is an analyst with an average return of -12.6% and a 35.94% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Insulet, and Dexcom.
Currently, the analyst consensus on Kestra Medical Technologies Ltd. is a Moderate Buy with an average price target of $30.00.